A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma

Trial Profile

A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2018 According to a SymBio Pharmaceuticals media release, first patient has been enrolled.
    • 05 Sep 2017 According to a SymBio Pharmaceuticals media release, company plans to file an NDA for relapsed/refractory diffuse large B-cell lymphomain the 2nd half of 2019.
    • 05 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top